Italia markets closed

FTSE MIB
33.922,16
+40,66(+0,12%)
Dow Jones
37.986,40
+211,02(+0,56%)
Nasdaq
15.282,01
-319,49(-2,05%)
Nikkei 225
37.068,35
-1.011,35(-2,66%)
Petrolio
83,24
+0,51(+0,62%)
Bitcoin EUR
59.959,62
+2.692,38(+4,70%)

NovoCure Limited (NVCR)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.

Aggiungi a watchlist

12,09

+0,04

(+0,33%)

Alla chiusura: 04:00PM EDT

12,19

+0,10

(+0,83%)

Dopo ore:

06:47PM EDT

I prezzi di scambio non provengono da tutti i mercati

Capitalizzazione	1,295B
Beta (5 anni mensile)	0,43
Rapporto PE (ttm)	N/D
EPS (ttm)	-1,95
Prossima data utili	02 mag 2024
Rendimento e dividendo (futuro)	N/D (N/D)
Data ex dividendo	N/D
Stima target 1A	27,33

Tutte

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in